Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · IEX Real-Time Price · USD
8.37
-0.06 (-0.71%)
At close: Jul 19, 2024, 4:00 PM
8.45
+0.08 (0.96%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $119.04M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $19.52M. In the year 2023, Voyager Therapeutics had annual revenue of $250.01M with 511.16% growth.
Revenue (ttm)
$119.04M
Revenue Growth
-37.58%
P/S Ratio
3.82
Revenue / Employee
$734,840
Employees
162
Market Cap
455.27M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
Dec 31, 2019 | 104.39M | 96.77M | 1,270.14% |
Dec 31, 2018 | 7.62M | -2.52M | -24.82% |
Dec 31, 2017 | 10.14M | -4.09M | -28.73% |
Dec 31, 2016 | 14.22M | -3.11M | -17.96% |
Dec 31, 2015 | 17.33M | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 522.74M |
Pacific Biosciences of California | 200.43M |
Theravance Biopharma | 61.51M |
EyePoint Pharmaceuticals | 50.02M |
MaxCyte | 44.05M |
Nano-X Imaging | 10.01M |
Absci | 5.35M |
Altimmune | 410.00K |
VYGR News
- 12 days ago - Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Voyager Therapeutics to Present at Multiple Virtual Investor Conferences - GlobeNewsWire
- 5 weeks ago - Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease - GlobeNewsWire
- 2 months ago - Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results - GlobeNewsWire
- 2 months ago - Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting - GlobeNewsWire
- 2 months ago - Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast - GlobeNewsWire
- 3 months ago - Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting - GlobeNewsWire